UNSW & Garvan Institute Take Precision Medicine Revolution to War Against Pancreatic Cancer in Australia
Thanks to an $3.75 million grant injection from the Cancer Institute, NSW Translational Program, researchers and clinicians from UNSW and […]
Thanks to an $3.75 million grant injection from the Cancer Institute, NSW Translational Program, researchers and clinicians from UNSW and […]
As January is Pancreatic Cancer Clinical Trials Awareness Month, TrialSite thought it was appropriate to introduce an important patient organization […]
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation status to an investigational drug called Ampligen (rintatolimod) for the […]
Prestige BioPharma Ltd. (hereinafter “Prestige BioPharma”) today announced that the European Medicines Agency (EMA) Orphan Drug Commission (COMP) has granted a […]
Kentucky’s Pikeville Medical Center is seeing positive results from a number of cancer-based clinical trials, including an investigational drug for pancreatic […]
At 80 years old, former U.S. Senator Harry M. Reid’s struggle with pancreatic cancer was close to the end. But […]
MD Anderson Cancer Center (“MDACC”) has resumed its investigator-initiated trial of an early stage pancreatic cancer therapy called SOR-C13 developed […]
A multi-department-based group of University of Pennsylvania researchers developed a machine-learning-based, liquid biopsy to detect early signs of the most […]
A prominent Spanish clinical investigational site, Clinica de Navarra (CUN) of Pamplona, helped save the life of a Gibraltar resident and […]
Pancreatic cancers actually utilize the same process used by sprinter’s muscles as they are about to race. How? Well as […]